Quest Diagnostics Incorporated’s Stock Price Drops to $140.96, Witnessing a 4.34% Decline: A Detailed Analysis

Quest Diagnostics Incorporated (DGX)

140.96 USD -6.39 (-4.34%) Volume: 1.89M

Quest Diagnostics Incorporated’s stock price stands at 140.96 USD, experiencing a downturn of -4.34% this trading session with a trading volume of 1.89M, yet maintaining a positive year-to-date growth of +2.23%, reflecting the resilience and potential growth of DGX’s stock performance.

Latest developments on Quest Diagnostics Incorporated

Quest Diagnostics reported strong second-quarter financial results, leading to a rise in their stock price on Monday, although it still underperformed the market. The company raised its guidance for the full year of 2024, citing increased demand for health tests. Analysts predict stable stock performance and modest growth in the future. Quest Diagnostics also completed its first quarter under new FDA rules on LDTs, further boosting investor confidence. With earnings and revenues surpassing estimates, the company raised its profit forecast for 2024. Additionally, Quest Diagnostics forecasts higher net revenues for the year, leading to increased investor interest and stock purchases by various advisory services and investment firms.

Quest Diagnostics Incorporated on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have provided bullish coverage on Quest Diagnostics. In their research reports, they highlight the company’s strong revenue growth across core services and major drivers for future success. Quest Diagnostics‘ focus on physicians and hospitals, investment in automation and AI, and reevaluation of full-year guidance have all contributed to nearly 6% base business revenue growth in Q1.

Baptista Research also notes Quest Diagnostics‘ continued investment in new technologies and automated solutions as key drivers for the company’s growth. They emphasize the company’s strategy to increase profitability and top-line growth across core customer channels. With a 7% revenue growth in the base business in 2023 and a shift away from COVID-19 testing, Quest Diagnostics is poised for further success. Baptista Research aims to provide an independent valuation of the company using a Discounted Cash Flow methodology to evaluate its future prospects.

A look at Quest Diagnostics Incorporated Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Quest Diagnostics has received a high Smart Score for its Dividend, indicating a strong outlook for the company’s dividend payments to shareholders. With a score of 5, Quest Diagnostics is considered to have a very positive dividend outlook, which may attract investors looking for stable returns.

Additionally, Quest Diagnostics has scored well in Value and Momentum, with scores of 4 each. This suggests that the company is seen as having good value relative to its stock price and shows positive momentum in its stock performance. While Growth and Resilience scores are slightly lower at 3, Quest Diagnostics still maintains a solid overall outlook based on the Smart Scores.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma